For the first time, we reported that miR-659–39 inhibits osteosarcoma cells growth in vitro and inhibits osteosarcoma tumor progression and metastasis in vivo by targeting SRPK1 gene expression. This evidence concerns the gene SRPK1 and neoplasm.